This article is more than 5 years old. Information may no longer be current.
BHVI, Contamac announce agreement for myopia products
Click Here to Manage Email Alerts
Contamac Ltd. and the Brien Holden Vision Institute recently announced that they have entered into an agreement that will allow for the distribution of myopia control products, according a press release issued by Contamac.
The multi-year license states that Contamac can market and distribute customized contact lenses for myopia control based on background intellectual property from the Brien Holden Vision Institute (BHVI), as detailed in the release.
“This is an important step in making effective myopia control technologies available to reduce the rate of progress of myopia and the risk of permanent vision impairment associated with high levels of myopia later in life,” Brien A. Holden, PhD, DSc, LOSc, CEO of the BHVI, said in the release. “Myopic macular degeneration is now the leading cause of new blindness in some locations in Asia, and with the number of myopes estimated to reach 2.2 billion by 2020 and the number of high myopes increasing rapidly, there is an urgent need for better interventions.”
Beginning in May 2015, Contamac "will begin to commercialize specialized contact lenses designed to reduce the rate of myopia progression in children by sub-licensing the Contamac designs to key strategic partners within its existing customer base throughout the world."
The technology utilized from the Brien Holden Vision Institute includes both foreign and U.S. patents, according to the release.
The release also stated that, as part of Contamac's plan, "a myopia control indication for use submission to the U.S. Food and Drug Administration is to be completed in early 2017."